-
$3,600 Original price was: $3,600.$3,000Current price is: $3,000.
Retatrutid is a peptide acting as a triple receptor agonist for GLP-1 receptors (GLP-1R), GIP receptors (GIPR), and glucagon receptors (GCGR). It enhances insulin secretion by activating GLP-1R, inhibits glucagon release, delays gastric emptying, and increases satiety; activates GIPR to enhance insulin sensitivity and regulate lipid metabolism; activates GCGR to promote energy expenditure, inhibit hepatic gluconeogenesis, and reduce hepatic fat deposition. This multi-target synergistic action makes it superior to traditional single-target GLP-1 drugs in lowering blood glucose, reducing body weight, and improving hepatic fat deposition.
The peptide will be provided as lyophilized powder to ensure maximum stability.
-
$3,500 Original price was: $3,500.$2,100Current price is: $2,100.
Retatrutid is a novel peptide drug, a triple receptor agonist acting on GLP-1, GIP, and glucagon receptors. It helps weight loss by regulating appetite, enhancing satiety, and increasing energy expenditure. It also improves cardiovascular-metabolic risk markers like blood pressure, HbA1c, fasting glucose, insulin, cholesterol, and triglycerides, and benefits non-alcoholic fatty liver disease patients by normalizing liver fat. Unlike single or dual agonists, Retatrutid’s triple action offers broader metabolic benefits, making it more effective for weight loss, liver fat reduction, and blood sugar normalization. It’s a promising new choice for obese and type 2 diabetic patients, especially those unresponsive to current treatments.
The peptide will be provided as lyophilized powder to ensure maximum stability.
End of content
End of content
